Abstract: SA-PO0772
Real-World (RW) Insights on How Health Care Providers (HCPs) Define Glomerular Inflammation in IgAN in the United States (US)
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Srinivas, Titte, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Haile-Meskale, Ruth, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Pivneva, Irina, Analysis Group Inc Boston, Boston, Massachusetts, United States
- Edwards, Marie Louise, Analysis Group Inc Boston, Boston, Massachusetts, United States
- Anderson, Annika, Analysis Group Inc Boston, Boston, Massachusetts, United States
- Sareen, Sinia, Analysis Group Inc Boston, Boston, Massachusetts, United States
- Signorovitch, James, Analysis Group Inc Boston, Boston, Massachusetts, United States
- Rastogi, Anjay, University of California Los Angeles, Los Angeles, California, United States
Background
IgAN is the most common form of primary glomerulonephritis globally. It is diagnosed via kidney biopsy and can be scored using the Oxford MEST-C classification system. Patients (pts) with IgAN exhibit variable levels of glomerular inflammation, but a clear phenotype definition is not yet established. This survey provides RW insights on how HCPs define glomerular inflammation in pts with IgAN.
Methods
US HCPs were invited to complete an online survey (main survey and an optional section; Feb–Mar 2025) to assess understanding of key terms related to IgAN severity/progression. Invited HCPs were board certified physicians, physician assistants, and nurse practitioners with nephrology specialty, responsible for treatment decisions of ≥1 pt with IgAN within ≤12 months. Data collected from consenting HCPs included clinical decision-making on treatments, understanding of IgAN-related terms, and availability of clinical data, summarized overall and by practice type; no pt-level data were collected. Data were summarized descriptively.
Results
Overall, 150 HCPs cared for a mean of 29 adults with IgAN in the past year; 125 completed the full survey (academic practice n=48; community practice n=70; other n=7) and were included in the analysis. The terms “persistent proteinuria” (87.2%) and “persistent hematuria” (58.4%) were commonly used across all practice types. The most common definitions (>1 allowed) of persistent proteinuria and hematuria included thresholds of >0.5 g/g and ≥5 red blood cells/high power field, respectively, for ≥90 days, in 2 samples. Most HCPs (92.0%) used the term “glomerular inflammation,” and the most common defining criteria included persistent proteinuria (76.5%), rapid estimated glomerular filtration rate (eGFR) decline (69.6%), MEST-C scores (66.1%), and persistent hematuria (52.2%). More HCPs in academic vs community practices included MEST-C scores to define glomerular inflammation (81.8% vs 57.8%).
Conclusion
In US clinical practice, “glomerular inflammation” in pts with IgAN was commonly used and defined by various criteria including persistent proteinuria/hematuria, rapid eGFR decline, and MEST-C scores; academic practices included MEST-C scores more often.
Funding
- Commercial Support – Novartis Pharmaceutical Corporation